Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125823 | 0.94 | NAMPT (0.38) | NAMPTPTGS2KDM4EHSD17B10EPHX2 | |
| SCHEMBL4135640 | 0.93 | NAMPT (0.37) | NAMPTPTGS2SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL3704869 | 0.91 | P2RX7 (0.37) | NAMPTPTGS2EPHX2 | |
| SCHEMBL4130559 | 0.90 | GAA (0.39) | NAMPTPTGS2SMN1; SMN2EPHX2RIPK1 | |
| SCHEMBL4134998 | 0.90 | NAMPT (0.38) | NAMPTPTGS2SMN1; SMN2CYP2C9ALDH1A1 | |
| SCHEMBL4125960 | 0.90 | NAMPT (0.38) | NAMPTPTGS2CYP2C9 | |
| SCHEMBL4131063 | 0.90 | NAMPT (0.38) | NAMPTPTGS2SMN1; SMN2DHODHCYP2C9 | |
| SCHEMBL4125915 | 0.90 | CNR1 (0.38) | NAMPTPTGS2 | |
| SCHEMBL4135106 | 0.89 | NAMPT (0.41) | NAMPTCYP3A4CTSASMN1; SMN2ALDH1A1 | |
| SCHEMBL4136915 | 0.89 | NAMPT (0.37) | NAMPTPTGS2SMN1; SMN2EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NAMPT 2129/4885PTGS2 269/4885CYP3A4 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.